Opportunity
Technical fit, rights, demand and commercial viability.
Services
Substantive capabilities for regulated pharmaceutical growth.
Eight connected service pillars support manufacturers, product owners, authorised suppliers, buyers and operational partners from opportunity review through launch readiness.
Connected services
Commercial progress should follow an unbroken line of evidence.
Each service pillar connects opportunity review, regulatory scope, partner qualification, quality controls, fulfilment and account-level evidence.
Opportunity and technical assessmentRegulatory and quality boundaryQualified partner and fulfilment routeControlled customer and document record
Connected evidence
Eight services. Four evidence boundaries.
Every service must preserve the same line from opportunity assessment to accountable fulfilment.
Permission
Company, product and market-specific regulatory boundaries.
Qualification
Supplier, quality, document and outsourced-activity evidence.
Execution
Controlled account, fulfilment, traceability and review records.
01
Who it is for
Pharmacies, wholesalers, hospitals, procurement teams and product owners
Pharmaceutical trading & distribution
Problem
Specialty supply can be fragmented, opaque and difficult to coordinate across regulatory and fulfilment boundaries.
NovaPharm approach
NovaPharm is preparing a B2B wholesale model that links qualified sourcing, controlled product records, documentation and third-party fulfilment oversight.
Operational value
A clearer route from opportunity assessment to compliant supply and account-level service.
Regulatory boundary: Regulated wholesale supply will begin only after the required WDA(H) and product permissions are in place.
Discuss UK distribution02
Who it is for
Dossier owners, authorised suppliers and qualified B2B buyers
PLPI regulatory & sourcing strategy
Problem
Not every medicine or source is suitable for a parallel-import route, and incomplete applications create avoidable delay and risk.
NovaPharm approach
Product opportunity assessment, simple, standard or complex pathway review, supplier qualification, documentation coordination, commercial viability analysis and licence-maintenance planning.
Operational value
A disciplined decision on whether a product-specific PLPI pathway is technically, regulatorily and commercially appropriate.
Regulatory boundary: Each activity remains subject to MHRA requirements and the grant of the relevant product-specific PLPI licence.
Speak to our regulatory team03
Who it is for
Licensed wholesalers, authorised distributors and UK procurement partners
European buying & sourcing
Problem
Single-market dependence can weaken continuity and limit price or availability options.
NovaPharm approach
Country and supplier screening, licence verification, vendor qualification, quality documentation, supply-continuity analysis and ongoing monitoring.
Operational value
A more diversified and evidence-led sourcing network across selected European markets.
Regulatory boundary: No supplier or product is represented as approved until due diligence and applicable authorisations are complete.
Become a supply partner04
Who it is for
Qualified manufacturers, CMOs, CDMOs and product owners
GMP manufacturing partnerships
Problem
UK market preparation requires alignment across technical evidence, quality governance, commercial terms and regulatory responsibilities.
NovaPharm approach
Manufacturer identification, technical assessment, quality agreements, technology-transfer support, CMO/CDMO coordination and launch-readiness planning.
Operational value
A controlled partnership pathway designed around UK and future EU requirements.
Regulatory boundary: GMP status and product rights are verified independently for each facility and opportunity.
Discuss CMO/CDMO collaboration05
Who it is for
Manufacturers, suppliers, licence holders and regulated partners
Quality, QMS & pharmacovigilance
Problem
Quality systems fail when responsibilities, evidence and escalation routes are fragmented.
NovaPharm approach
SOP and document governance, deviations, CAPA, complaints, audits, training, recall readiness, adverse-event escalation and data-integrity controls.
Operational value
A traceable quality framework that supports audit readiness and patient-safety responsibilities.
Regulatory boundary: Formal regulated responsibilities are assigned only to appropriately qualified and authorised people.
Discuss quality readiness06
Who it is for
B2B buyers, supply partners and logistics providers
Logistics & distribution operations
Problem
Pharmaceutical fulfilment requires controlled storage, transport, batch, expiry and outsourced-activity oversight.
NovaPharm approach
A capital-efficient third-party logistics model covering ambient and controlled-temperature requirements, import/export documentation, order fulfilment and performance reporting.
Operational value
Scalable distribution planning without presenting infrastructure ownership as an achieved capability.
Regulatory boundary: Polar Speed/Marken integration and service scope remain subject to final contracts, authorisations and technical onboarding.
Discuss logistics integration07
Who it is for
Customers, employees, board members and integration partners
Digital B2B & data services
Problem
Manual ordering and disconnected documents create delay, weak visibility and duplicated work.
NovaPharm approach
Role-based account, order, inventory, document and reporting services built around a shared data model and Microsoft 365 document backbone.
Operational value
A controlled digital route from customer record to order, document and audit trail.
Regulatory boundary: Portal workflows are in development; AI forecasting and batch-level traceability remain roadmap capabilities.
Explore our technology08
Who it is for
Product owners, pharmacies, wholesalers, hospital procurement and commercial partners
UK market access & partnerships
Problem
A UK opportunity needs more than a product: it needs a credible route through regulatory, quality, supply and customer-readiness decisions.
NovaPharm approach
Stakeholder mapping, opportunity assessment, partner due diligence, launch preparation and account-onboarding design.
Operational value
A practical view of what must be true before a responsible UK launch can proceed.
Regulatory boundary: NovaPharm does not claim current NHS supply or framework participation unless independently verified.
Discuss a partnershipStart a qualified conversation